Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L6ND
|
||||
| Former ID |
DNC010159
|
||||
| Drug Name |
AGELADINE A
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H7Br2N5
|
||||
| Canonical SMILES |
C1=CN=C(C2=C1NC(=N2)N)C3=CC(=C(N3)Br)Br
|
||||
| InChI |
1S/C10H7Br2N5/c11-4-3-6(15-9(4)12)7-8-5(1-2-14-7)16-10(13)17-8/h1-3,15H,(H3,13,16,17)
|
||||
| InChIKey |
QAKGJAQGTQLMFN-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | MMP-12 | Target Info | Inhibitor | [1] | |
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Degradation of collagen | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2009 Sep 15;19(18):5461-3. Epub 2009 Jul 23.Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.